phentolamine mesilate
phentolamine mesilate.JPG

CLINICAL USE

Alpha-adrenoceptor blocker:Hypertensive crisis

DOSE IN NORMAL RENAL FUNCTION

2–5 mg repeated if necessary

PHARMACOKINETICS

  • Molecular weight                           :377.5
  • %Protein binding                           :54
  • %Excreted unchanged in urine     : 13
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :19 minutes/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function Titrate dose to end point, i.e. lower BP

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Dose as in normal renal function
  • HD                     :Unknown dialysability. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Anaesthetics: enhanced hypotensive effect
  • Antidepressants: additive hypotensive effect with MAOIs – avoid concomitant useAntihypertensives: enhanced hypotensive effect
  • Diuretics: enhanced hypotensive effect Linezolid: additive hypotensive effect
  • Moxisylyte: possibly severe postural hypotension
  • Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid concomitant use

    ADMINISTRATION

    Reconstition

    Route

    IV

    Rate of Administration

    Comments

    OTHER INFORMATION

    Titrate according to response



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs